• Mashup Score: 5
    Management of CNS Lymphoma | Blood Cancer Talks | Episode 32 - 8 month(s) ago

    In this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes: 1. ASH 2022 data on PET scan in CNS lymphoma -…

    Source: share.transistor.fm
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of BloodCancerTalk
      BloodCancerTalk

      Tune in to our new episode on management of CNS lymphoma with @CwynKate. We discuss primary & secondary CNS lymphoma as well as the contentious topic of CNS prophylaxis! https://t.co/V3yhzMvu4b #lymsm #bmtsm Check out this clip on cytarabine dose modification in CNS lymphoma: https://t.co/OG1vIylS5V

  • Mashup Score: 2
    Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation - 8 month(s) ago

    Autologous haematopoietic stem-cell transplantation (HSCT) involves collecting the stem cells of a patient, administering high-dose chemotherapy or radiation to eradicate the underlying haematological disease, and then reinfusing the collected stem cells to restore bone marrow. This procedure allows for the administration of high-dose chemotherapy while minimising damage to the bone marrow and immune system. Autologous HSCT has shown success in achieving complete remission and even long-term survival for some lymphoma subtypes.

    Source: www.thelancet.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrRaulCordoba
      DrRaulCordoba

      #Hematology Beyond remission: secondary primary malignancies in patients with #lymphoma after autologous haematopoietic stem-cell transplantation #ASCT - ⁦@TheLancetHaem⁩ by ⁦@AnnaSureda5⁩ & ⁦@Evadodo23⁩ #lymsm #bmtsm #survonc https://t.co/OjMFdjf9pY

  • Mashup Score: 1
    CAR T-cell therapy in autoimmune diseases - 8 month(s) ago

    Despite the tremendous progress in the clinical management of autoimmune diseases, many patients do not respond to the currently used treatments. Autoreactive B cells play a key role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. B-cell-depleting monoclonal antibodies, such as rituximab, have poor therapeutic efficacy in autoimmune diseases, mainly due to the persistence of autoreactive B cells in lymphatic organs and inflamed tissues.

    Source: www.thelancet.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      CAR T-cell therapy in autoimmune diseases - The Lancet https://t.co/VaF7FvtwEe #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy @TheLancet

  • Mashup Score: 1
    Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 - 8 month(s) ago

    Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with cancer and COVID-19.

    Source: aacrjournals.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR https://t.co/IMEbvgZafi #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm https://t.co/0gTI5wdd36

Load More